공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

파킨슨병 : 파이프라인 리뷰

Parkinson´s Disease (Central Nervous System) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 229809
페이지 정보 영문 1584 Pages
가격
US $ 2,500 ₩ 2,993,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,987,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,981,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


파킨슨병 : 파이프라인 리뷰 Parkinson´s Disease (Central Nervous System) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 1584 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

파킨슨병은 운동기능 장애라는 특징이 있는 신경변성 장애이며, 안정시 손떨림, 근육 경직, 운동기관의 기능 장애를 일으킵니다. 소인은 나이, 유전적 요인, 머리 외상, 환경적 요인, 호르몬 변화 등이 있습니다. 파킨슨병에 의해 신경기능 이상이 발생하거나, 세포가 사멸되기도 합니다. 신경세포는 원래 신경전달물질 도파민의 합성을 담당하고 있으며, 신경이 영향을 받아 효과적인 신경 전달을 방해하게 되고, 운동 기능과 근육의 조절 능력이 저하됩니다.

파킨슨병(Parkinson´s Disease) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관에 의해서 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

파킨슨병 개요

치료제 개발

파킨슨병 : 기업에서 개발중인 치료제

파킨슨병 : 대학/기관에서 연구중인 치료제

파킨슨병 : 파이프라인 제품 개요

파킨슨병 : 기업에서 개발중인 제품

파킨슨병 : 대학/기관에서 연구중인 제품

파킨슨병 치료제 개발에 참여하고 있는 기업

파킨슨병 : 치료제 평가

약제 개요

파킨슨병 : 휴지중인 프로젝트

파킨슨병 : 개발이 중지된 제품

파킨슨병 : 제품 개발 마일스톤

부록

KSM 16.08.03

List of Tables

List of Tables

  • Number of Products under Development for Parkinson's Disease, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Parkinson's Disease - Pipeline by 1st Bio Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by 3Z ehf, 2021
  • Parkinson's Disease - Pipeline by 4D Pharma Plc, 2021
  • Parkinson's Disease - Pipeline by Abaxy Sprl, 2021
  • Parkinson's Disease - Pipeline by AbbVie Inc, 2021
  • Parkinson's Disease - Pipeline by Abfero Pharmaceuticals Inc, 2021
  • Parkinson's Disease - Pipeline by Abivax SA, 2021
  • Parkinson's Disease - Pipeline by ABL Bio Inc, 2021
  • Parkinson's Disease - Pipeline by AC Immune SA, 2021
  • Parkinson's Disease - Pipeline by Accure Therapeutics SL, 2021
  • Parkinson's Disease - Pipeline by Acelot Inc, 2021
  • Parkinson's Disease - Pipeline by Addex Therapeutics Ltd, 2021
  • Parkinson's Disease - Pipeline by Adicet Bio Inc, 2021
  • Parkinson's Disease - Pipeline by Affamed Therapeutics HK Ltd, 2021
  • Parkinson's Disease - Pipeline by AFFiRiS AG, 2021
  • Parkinson's Disease - Pipeline by AgoneX Biopharmaceuticals Inc, 2021
  • Parkinson's Disease - Pipeline by Akome Biotech Ltd, 2021
  • Parkinson's Disease - Pipeline by Alan Laboratories Inc, 2021
  • Parkinson's Disease - Pipeline by Alar Pharmaceuticals Inc, 2021
  • Parkinson's Disease - Pipeline by Alector Inc, 2021
  • Parkinson's Disease - Pipeline by Alectos Therapeutics, 2021
  • Parkinson's Disease - Pipeline by Alexza Pharmaceuticals Inc, 2021
  • Parkinson's Disease - Pipeline by Alkahest Inc, 2021
  • Parkinson's Disease - Pipeline by Alkermes Plc, 2021
  • Parkinson's Disease - Pipeline by AlphaCognition Inc, 2021
  • Parkinson's Disease - Pipeline by Alsonex Pty Ltd, 2021
  • Parkinson's Disease - Pipeline by Alterity Therapeutics Ltd, 2021
  • Parkinson's Disease - Pipeline by AlzeCure Pharma AB, 2021
  • Parkinson's Disease - Pipeline by Amathus Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by Amneal Pharmaceuticals Inc, 2021
  • Parkinson's Disease - Pipeline by Anavex Life Sciences Corp, 2021
  • Parkinson's Disease - Pipeline by Annovis Bio Inc, 2021
  • Parkinson's Disease - Pipeline by Antoxis Ltd, 2021
  • Parkinson's Disease - Pipeline by Aoxing Pharmaceutical Company Inc, 2021
  • Parkinson's Disease - Pipeline by Appello Pharmaceuticals Inc, 2021
  • Parkinson's Disease - Pipeline by Aprinoia Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by AptaBio Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by Aptamer Sciences Inc, 2021
  • Parkinson's Disease - Pipeline by Aranda Pharma Ltd, 2021
  • Parkinson's Disease - Pipeline by AriBio, 2021
  • Parkinson's Disease - Pipeline by ArmaGen Inc, 2021
  • Parkinson's Disease - Pipeline by Arrien Pharmaceuticals LLC, 2021
  • Parkinson's Disease - Pipeline by ArunA Biomedical Inc, 2021
  • Parkinson's Disease - Pipeline by Arvinas Inc, 2021
  • Parkinson's Disease - Pipeline by Asceneuron SA, 2021
  • Parkinson's Disease - Pipeline by Asdera LLC, 2021
  • Parkinson's Disease - Pipeline by Ashvattha Therapeutics LLC, 2021
  • Parkinson's Disease - Pipeline by Asklepios BioPharmaceutical Inc, 2021
  • Parkinson's Disease - Pipeline by Aspen Neuroscience Inc, 2021
  • Parkinson's Disease - Pipeline by Astellas Pharma Inc, 2021
  • Parkinson's Disease - Pipeline by AstraZeneca Plc, 2021
  • Parkinson's Disease - Pipeline by Caraway Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by Carmot Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by Carna Biosciences Inc, 2021
  • Parkinson's Disease - Pipeline by Casma Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by CavoGene LifeSciences, 2021
  • Parkinson's Disease - Pipeline by Celavie Biosciences LLC, 2021
  • Parkinson's Disease - Pipeline by CellCure, 2021
  • Parkinson's Disease - Pipeline by Cellivery Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by Cellix Bio Pvt Ltd, 2021
  • Parkinson's Disease - Pipeline by Celros Biotech Co Ltd, 2021
  • Parkinson's Disease - Pipeline by Cerecin Pte Ltd, 2021
  • Parkinson's Disease - Pipeline by CereSpir Inc, 2021
  • Parkinson's Disease - Pipeline by Coave Therapeutics, 2021
  • Parkinson's Disease - Pipeline by Cogentis Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by Cognition Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by Collaborative Medicinal Development LLC, 2021
  • Parkinson's Disease - Pipeline by Contera Pharma ApS, 2021
  • Parkinson's Disease - Pipeline by Convalesce Inc, 2021
  • Parkinson's Disease - Pipeline by Copernicus Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by Corium Inc, 2021
  • Parkinson's Disease - Pipeline by Cortexyme Inc, 2021
  • Parkinson's Disease - Pipeline by Coya Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by Fulcrum Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by Gain Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by GB Sciences Inc, 2021
  • Parkinson's Disease - Pipeline by Gene Therapy Research Institution Co Ltd, 2021
  • Parkinson's Disease - Pipeline by Generoath Co Ltd, 2021
  • Parkinson's Disease - Pipeline by Genervon Biopharmaceuticals LLC, 2021
  • Parkinson's Disease - Pipeline by GenKyoTex SA, 2021
  • Parkinson's Disease - Pipeline by Genmab AS, 2021
  • Parkinson's Disease - Pipeline by Gismo Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by GL Pharm Tech Corp, 2021
  • Parkinson's Disease - Pipeline by Global BioLife Inc Ltd, 2021
  • Parkinson's Disease - Pipeline by GNT Pharma Co Ltd, 2021
  • Parkinson's Disease - Pipeline by GraySpace Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by Grespo AB, 2021
  • Parkinson's Disease - Pipeline by Guangdong East Sunshine Pharmaceutical Co Ltd, 2021
  • Parkinson's Disease - Pipeline by Guangzhou DM Intelligence Ltd, 2021
  • Parkinson's Disease - Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, 2021
  • Parkinson's Disease - Pipeline by H. Lundbeck AS, 2021
  • Parkinson's Disease - Pipeline by Hangzhou Zede Pharmaceutical Technology Co Ltd, 2021
  • Parkinson's Disease - Pipeline by Hebei Newtherapy BIo-Pharma Technology Co Ltd, 2021
  • Parkinson's Disease - Pipeline by Help Therapeutics, 2021
  • Parkinson's Disease - Pipeline by Herantis Pharma Plc, 2021
  • Parkinson's Disease - Pipeline by Hillhurst Biopharmaceuticals Inc, 2021
  • Parkinson's Disease - Pipeline by Mitsubishi Tanabe Pharma Corp, 2021
  • Parkinson's Disease - Pipeline by Modag GmbH, 2021
  • Parkinson's Disease - Pipeline by Molomics Biotech SL, 2021
  • Parkinson's Disease - Pipeline by Montisera Ltd, 2021
  • Parkinson's Disease - Pipeline by Motac Neuroscience Ltd, 2021
  • Parkinson's Disease - Pipeline by Neonc Technologies Inc, 2021
  • Parkinson's Disease - Pipeline by Netherlands Translational Research Center BV, 2021
  • Parkinson's Disease - Pipeline by NeuExcell Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by Neuracle Science Co Ltd, 2021
  • Parkinson's Disease - Pipeline by Neuraly Inc, 2021
  • Parkinson's Disease - Pipeline by Neuramedy Co Ltd, 2021
  • Parkinson's Disease - Pipeline by Neuren Pharmaceuticals Ltd, 2021
  • Parkinson's Disease - Pipeline by Neuro Vigor LLC, 2021
  • Parkinson's Disease - Pipeline by Neurocea Pharmaceuticals, 2021
  • Parkinson's Disease - Pipeline by Neurochlore, 2021
  • Parkinson's Disease - Pipeline by Neurodon LLC, 2021
  • Parkinson's Disease - Pipeline by Neuroene Therapeutics LLC, 2021
  • Parkinson's Disease - Pipeline by NeuroGeneration Inc, 2021
  • Parkinson's Disease - Pipeline by Neuron23 Inc, 2021
  • Parkinson's Disease - Pipeline by Neurona Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by NeuroNascent Inc, 2021
  • Parkinson's Disease - Pipeline by NeuroPn Therapeutics LLC, 2021
  • Parkinson's Disease - Pipeline by Neuropore Therapies Inc, 2021
  • Parkinson's Disease - Pipeline by New Amsterdam Sciences Inc, 2021
  • Parkinson's Disease - Pipeline by New Biotic Inc, 2021
  • Parkinson's Disease - Pipeline by New World Laboratories Inc, 2021
  • Parkinson's Disease - Pipeline by Newron Pharmaceuticals SpA, 2021
  • Parkinson's Disease - Pipeline by Nexmos Inc, 2021
  • Parkinson's Disease - Pipeline by Nitrome Biosciences Inc, 2021
  • Parkinson's Disease - Pipeline by nLife Therapeutics SL, 2021
  • Parkinson's Disease - Pipeline by NLS Pharma Group, 2021
  • Parkinson's Disease - Pipeline by Novartis AG, 2021
  • Parkinson's Disease - Pipeline by Novo Nordisk AS, 2021
  • Parkinson's Disease - Pipeline by NRG Therapeutics Ltd, 2021
  • Parkinson's Disease - Pipeline by NTZ Lab Ltd, 2021
  • Parkinson's Disease - Pipeline by NutriBand Inc, 2021
  • Parkinson's Disease - Pipeline by Ohara Pharmaceutical Co Ltd, 2021
  • Parkinson's Disease - Pipeline by Omeros Corp, 2021
  • Parkinson's Disease - Pipeline by Oncodesign SA, 2021
  • Parkinson's Disease - Pipeline by Orphazyme A/S, 2021
  • Parkinson's Disease - Pipeline by Orpheris Inc, 2021
  • Parkinson's Disease - Pipeline by Oryzon Genomics SA, 2021
  • Parkinson's Disease - Pipeline by Oxyrane Belgium NV, 2021
  • Parkinson's Disease - Pipeline by Parkure Ltd, 2021
  • Parkinson's Disease - Pipeline by Peptron Inc, 2021
  • Parkinson's Disease - Pipeline by Pfizer Inc, 2021
  • Parkinson's Disease - Pipeline by Pharma Two B Ltd, 2021
  • Parkinson's Disease - Pipeline by PharmaTher Holdings Ltd, 2021
  • Parkinson's Disease - Pipeline by PharmatrophiX Inc, 2021
  • Parkinson's Disease - Pipeline by Phoenix Biotechnology Inc, 2021
  • Parkinson's Disease - Pipeline by Phoenix Life Sciences International Ltd, 2021
  • Parkinson's Disease - Pipeline by PK Biosciences Corp, 2021
  • Parkinson's Disease - Pipeline by Plex Pharmaceuticals Inc, 2021
  • Parkinson's Disease - Pipeline by Polaryx Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by PolyCore Therapeutics LLC, 2021
  • Parkinson's Disease - Pipeline by Praxis Precision Medicines Inc, 2021
  • Parkinson's Disease - Pipeline by Priavoid GmbH, 2021
  • Parkinson's Disease - Pipeline by Prilenia Therapeutics Development Ltd, 2021
  • Parkinson's Disease - Pipeline by Vincere Biosciences Inc, 2021
  • Parkinson's Disease - Pipeline by Vivifi Biotech Ltd, 2021
  • Parkinson's Disease - Pipeline by Vivreon Biosciences LLC, 2021
  • Parkinson's Disease - Pipeline by Voyager Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by Whan In Pharm Co Ltd, 2021
  • Parkinson's Disease - Pipeline by Wren Therapeutics Ltd, 2021
  • Parkinson's Disease - Pipeline by Xcelthera INC, 2021
  • Parkinson's Disease - Pipeline by Xoc Pharmaceuticals Inc, 2021
  • Parkinson's Disease - Pipeline by XYnapse Therapeutics Pty Ltd, 2021
  • Parkinson's Disease - Pipeline by Yuhan Corp, 2021
  • Parkinson's Disease - Pipeline by Yumanity Therapeutics Inc, 2021
  • Parkinson's Disease - Pipeline by Zhittya Genesis Medicine Inc, 2021
  • Parkinson's Disease - Dormant Projects, 2021
  • Parkinson's Disease - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Parkinson's Disease, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease - Drugs In Development, 2021, provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape.Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 10, 55, 85, 5, 254, 133 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 55 and 18 molecules, respectively.

Parkinson's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson's Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Parkinson's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Parkinson's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Parkinson's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson's Disease (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Parkinson's Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Parkinson's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Parkinson's Disease - Overview
  • Parkinson's Disease - Therapeutics Development
  • Parkinson's Disease - Therapeutics Assessment
  • Parkinson's Disease - Companies Involved in Therapeutics Development
  • Parkinson's Disease - Drug Profiles
  • Parkinson's Disease - Dormant Projects
  • Parkinson's Disease - Discontinued Products
  • Parkinson's Disease - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q